First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Clinical trial NCT06730373 · RECRUITING

Trial details

NCT number: NCT06730373
Sponsor: Qilu Hospital of Shandong University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Gastric Cancer Metastatic Gastric Cancer Unresectable Gastric Carcinoma

Start date: 2024-10-17
Primary completion: 2026-12-31
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.